The research aimed to study the efficacy of ch-OSA® on symptomatic osteoarthritis of the knee
WHAT WE FOUND
Researchers found a significant improvement in men taking ch-OSA® compared to men in the placebo group. After 12 weeks, men taking ch-OSA® reported:
26% less knee discomfort than men in the placebo group
35% less knee stiffness than men in the placebo group
25% better daily function than men in the placebo group
The improvement in cartilage degradation was also markedly better for men taking ch-OSA®. Biochemical markers of collagen degradation in the blood and urine were significantly lowered. After 12 weeks, researchers found that men taking ch-OSA® had:
25% less CTX-II (C-telopeptide fragments of collagen type II) than men in the placebo group
19% less COMP (cartilage oligomeric matrix protein) than men in the placebo group
The participants were 166 people (120 women and 46 men); between the ages of 50 and 75, with clear symptoms of cartilage loss in the knee.
Figure 1: The reported discomfort, stiffness, and difficulty performing daily functions of men with knee osteoarthritis; men who took ch-OSA® versus men in the control group. WOMAC is a widely-used and validated self-assessment measurement for how joint health impacts people.
Figure 2: The presence of biochemical markers of cartilage degradation in men who took ch-OSA® versus men in the control group.
The researchers believe the observed improvements in joint discomfort and mobility are due to the positive effects of ch-OSA® on collagen in cartilage, ligaments, tendons, and bone.